Novel opioid could provide pain relief alternative to fentanyl
NFEPP, a new opioid, inhibited colon pain in mice with colitis but did not cause the side effects associated with use of fentanyl.
List view / Grid view
NFEPP, a new opioid, inhibited colon pain in mice with colitis but did not cause the side effects associated with use of fentanyl.
Although a cure for HIV continues to elude scientists, strategies to control the virus and immunise people are developing at rapid pace. Here, Drug Target Review’s Victoria Rees discusses why researchers are focusing on antibodies as approaches to combat HIV and highlights recent findings from two pre-clinical studies into how…
A combination of checkpoint and small molecule inhibitors showed success at targeting Myc oncogenes in mouse neuroblastoma and melanoma models.
In this article, Dr Lien Lybaert describes how the innate and adaptive immune system work together to produce an effective and durable antitumour response. She explains why the best strategy for personalised cancer therapy is therefore to identify major histocompatibility (MHC) binding epitopes to cover the full antigenic repertoire of…
In this Q&A, Dr Taha Merghoub discusses how a combination of glycolytic-pathway inhibition and immune checkpoint blockade using anti-CTLA-4 in patients with highly glycolytic tumours could present a personalised approach for immuno-oncology.
With the ongoing COVID-19 pandemic, new treatments continue to be urgently needed. One potential solution is antibody therapeutics, which can be used to neutralise the coronavirus and provide future immunity to patients. Here, Dr Laura Walker from Adagio Therapeutics discusses how antibodies can be used in the fight against Severe…
Recent years have seen an increase in the development of biomaterial and nanoparticle-based vaccine formulations. Sushma Kumari, Sonal Asthana and Kaushik Chatterjee from the Department of Materials Engineering at the Indian Institute of Science discuss why these materials have such high potential in the fight against infectious diseases.
This ebook includes articles discussing why biomaterial and nanoparticle-based formulations could lead to the next generation of vaccines and exploring how a new rhinovirus vaccine showed promise in pre-clinical studies.
Within this ebook, find articles on how a lead bNAb candidate was identified to combat COVID-19 and why antibodies could present the answer to HIV treatment and vaccines.
31 March 2021 | By
The new AdvanceBio Sialic Acid profiling and quantitation kit from Agilent provides workflows for the robust and rapid preparation of samples for sialic acid analysis, generating reliable downstream LC-FLD and LC-MS data.
The multiple serotypes of rhinovirus have presented difficulties for vaccine developers. Now, a team led by Professor Gary McLean from London Metropolitan University and Imperial College London, alongside Professor Sebastian Johnston from Imperial, has formulated a potential vaccine. Nikki Withers spoke to McLean to discover how the vaccine works and…
Don’t miss the latest product hub from Fluidic Analytics, detailing the Fluidity One-W Serum which enables comprehensive profiling of protein-protein interactions, such as the antibody response to SARS-CoV-2, based on affinity – a crucial characteristic of protein interactions that traditional tests cannot easily quantify.
A novel artificial intelligence (AI) technique called ProteinGAN has shown success at studying well known proteins to develop new ones.
Researchers have shown that prime editing is able to effectively edit genes in mice but without the off-target effects of CRISPR.
Researchers have revealed that T cells in blood samples from people who recovered from COVID-19 responded to SARS-CoV-2 variants.